by Gertrud U. Rey Almost sixty years have passed since the initial formalin-inactivated respiratory syncytial virus (RSV) vaccine caused enhanced disease in children when they were subsequently infected with the virus. Since then, RSV has continued to be a substantial public health threat to infants, young children, and older people. Although progress in developing a …
pre-fusion spike protein
On February 27, 2021, the FDA issued an emergency use authorization for a one-dose SARS-CoV-2 vaccine developed by Janssen Pharmaceutica, a Belgium-based division of Johnson & Johnson.
The mRNA vaccine platform is based on decades of previous studies, highlighting the importance of regularly funding basic research.